Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Axpim
2. Bmy 28142
3. Bmy-28142
4. Bmy28142
5. Cefepim
6. Cefepime Hydrochloride
7. Maxipime
8. Quadrocef
1. Maxipime
2. 88040-23-7
3. Cefepima
4. Cefepimum [latin]
5. Cefepima [spanish]
6. Cefepimum
7. Bmy-28142
8. Cfpm
9. Axepim
10. (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
11. 807pw4vqe3
12. 1-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium Hydroxide, Inner Salt, 7(sup 2)-(z)-(o-methyloxime)
13. Vnrx-5022
14. Chebi:478164
15. J01de01
16. Bmy 28142
17. (6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
18. Cefepime (usan/inn)
19. Unii-807pw4vqe3
20. Cefepime [usan:inn:ban]
21. Cefepime, Antibiotic For Culture Media Use Only
22. Cefepime [usan]
23. Cefepime [inn]
24. Cefepime [mi]
25. Cefepime [vandf]
26. Cefepime [who-dd]
27. Chembl186
28. Schembl65720
29. Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, Hydroxide, Inner Salt, (6r-(6alpha,7beta(z)))-
30. Dtxsid70873208
31. Bcpp000292
32. Hms2089m18
33. Hy-b0692
34. Bdbm50350470
35. Akos015850865
36. Akos016014147
37. Bcp9000504
38. Db01413
39. 7beta-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
40. As-76125
41. Cs-0009590
42. C-2468
43. C08111
44. D02376
45. Ab01275446-01
46. Q27294816
47. 1-{[(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium
48. Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, Hydroxide, Inner Salt, (6r-(6.alpha.,7.beta.(z)))-
| Molecular Weight | 480.6 g/mol |
|---|---|
| Molecular Formula | C19H24N6O5S2 |
| XLogP3 | -0.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | 480.12496023 g/mol |
| Monoisotopic Mass | 480.12496023 g/mol |
| Topological Polar Surface Area | 204 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 869 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Maxipime |
| PubMed Health | Cefepime (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | MAXIPIME (cefepime hydrochloride, USP) is a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. The chemical name is 1-[[(6R,7R)-7-[2-(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0] o... |
| Active Ingredient | Cefepime hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2gm base/vial; eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hospira |
| 2 of 2 | |
|---|---|
| Drug Name | Maxipime |
| PubMed Health | Cefepime (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | MAXIPIME (cefepime hydrochloride, USP) is a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. The chemical name is 1-[[(6R,7R)-7-[2-(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0] o... |
| Active Ingredient | Cefepime hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2gm base/vial; eq 500mg base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Hospira |
For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
FDA Label
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacteriaceae, and multiple drug resistant Streptococcus pneumoniae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DE - Fourth-generation cephalosporins
J01DE01 - Cefepime
Absorption
The absolute bioavailability of cefepime after an IM dose of 50 mg/kg was 82.3 (±15)% in eight patients.
Route of Elimination
Elimination of cefepime is principally via renal excretion with an average (SD) half-life of 2 (0.3) hours and total body clearance of 120 (8) mL/min in healthy volunteers. Cefepime is excreted in human milk.
Volume of Distribution
18.0 2.0 L
0.3 0.1 L/kg [Pediatric]
Clearance
120 mL/min [Healthy adult male receiving a single 30-minute IV infusions of cefepime]
3.3 +/-1.0 mL/min/kg [Petriatic patients (2 months 11 years of age) receiving a single IV dose]
Hepatic. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide).
2.0 (± 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (± 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (± 2.0) hours.
Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).
API SUPPLIERS
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25913
Submission : 2012-05-05
Status : Active
Type : II
Certificate Number : R1-CEP 2012-242 - Rev 00
Issue Date : 2019-08-16
Type : Chemical
Substance Number : 2126
Status : Valid
Date of Issue : 2016-09-06
Valid Till : 2019-07-02
Written Confirmation Number : WC-0145
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-24
Pay. Date : 2013-06-14
DMF Number : 19806
Submission : 2006-09-26
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-15
Pay. Date : 2016-07-05
DMF Number : 24395
Submission : 2011-03-31
Status : Active
Type : II
Certificate Number : R0-CEP 2023-021 - Rev 00
Issue Date : 2023-07-27
Type : Chemical
Substance Number : 2126
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-17
Pay. Date : 2013-08-07
DMF Number : 25303
Submission : 2011-09-15
Status : Active
Type : II
Certificate Number : R1-CEP 2011-286 - Rev 01
Issue Date : 2021-12-21
Type : Chemical
Substance Number : 2126
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19755
Submission : 2006-09-07
Status : Inactive
Type : II
Certificate Number : R0-CEP 2007-134 - Rev 01
Issue Date : 2013-02-07
Type : Chemical
Substance Number : 2126
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21139
Submission : 2007-12-14
Status : Inactive
Type : II
Certificate Number : R1-CEP 2008-212 - Rev 01
Issue Date : 2018-02-23
Type : Chemical
Substance Number : 2126
Status : Withdrawn by Holder
Certificate Number : R1-CEP 2007-205 - Rev 06
Issue Date : 2022-11-07
Type : Chemical
Substance Number : 2126
Status : Valid
Date of Issue : 2022-08-31
Valid Till : 2025-07-14
Written Confirmation Number : WC-0090
Address of the Firm :
Certificate Number : CEP 2008-081 - Rev 03
Issue Date : 2024-09-09
Type : Chemical
Substance Number : 2126
Status : Valid
Date of Issue : 2019-07-22
Valid Till : 2022-07-21
Written Confirmation Number : WC-0131
Address of the Firm :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Cipla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Cipla
Deal Size : Undisclosed
Deal Type : Collaboration
Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India
Details : Through the collaboration Orchid & Cipla will launch Exblifep (cefepime/enmetazobactam), which is indicated for the treatment of complicated urinary tract infections, including pyelonephritis.
Brand Name : Exblifep
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 29, 2024
Details:
Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Allecra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 25, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Allecra Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Allecra and Acino sign deal for Exblifep antibiotic in GCC, South Africa
Details : Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance.
Brand Name : Exblifep
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 25, 2024
Details:
Exblifep (cefepime/enmetazobactam) is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Orchid Pharma Receives DCGI Approval for Cefepime & Enmetazobactam Antibiotic
Details : Exblifep (cefepime/enmetazobactam) is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Brand Name : Exblifep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2024
Details:
UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Lead Product(s) : Enmetazobactam,Cefepime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UK MHRA Approves Advanz Pharma Antibiotic for Complex Infections
Details : UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.
Brand Name : Exblifep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2024
Details:
WCK 5222, a combination of cefepime and zidebactam, is in a Phase 3 trial for complicated urinary tract infections globally.
Lead Product(s): Cefepime,Zidebactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: WCK 5222
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: ICICI Prudential
Deal Size: $57.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 28, 2024
Lead Product(s) : Cefepime,Zidebactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : ICICI Prudential
Deal Size : $57.5 million
Deal Type : Private Placement
Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial
Details : WCK 5222, a combination of cefepime and zidebactam, is in a Phase 3 trial for complicated urinary tract infections globally.
Brand Name : WCK 5222
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2024
Details:
Exblifep (cefepime/enmetazobactam) is designed to combat antimicrobial resistance in gram-negative bacteria, indicated for complicated urinary tract infections in patients aged 18 and older.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Exblifep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Lead Product(s) : Cefepime,Enmetazobactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Allecra Therapeutics Gets FDA Approval for EXBLIFEP® for Urinary Tract Infections
Details : Exblifep (cefepime/enmetazobactam) is designed to combat antimicrobial resistance in gram-negative bacteria, indicated for complicated urinary tract infections in patients aged 18 and older.
Brand Name : Exblifep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2024
Details:
VNRX-5022 (cefepime) & taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor, is under development for treating complicated urinary tract infections and bacterial pneumonia in adults.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: VNRX-5022
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Melinta Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Melinta Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Venatorx and Melinta Update on U.S. NDA for Cefepime-Taniborbactam
Details : VNRX-5022 (cefepime) & taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor, is under development for treating complicated urinary tract infections and bacterial pneumonia in adults.
Brand Name : VNRX-5022
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2024
Details:
Menarini will acquire rights to commercialize VNRX-5022/VNRX-5133 (cefepime-taniborbactam), an investigational antibiotic for complicated urinary tract infections, in 96 countries.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: VNRX-5022
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Menarini
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2024
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Menarini
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Venatorx and Menarini Enter Commercial Agreement for Cefepime-Taniborbactam
Details : Menarini will acquire rights to commercialize VNRX-5022/VNRX-5133 (cefepime-taniborbactam), an investigational antibiotic for complicated urinary tract infections, in 96 countries.
Brand Name : VNRX-5022
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 09, 2024
Details:
The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: VenatoRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 09, 2023
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : VenatoRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adu...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2023
Details:
Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor antibiotic being developed by Venatorx Pharmaceuticals for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor antibiotic being developed by Venatorx Pharmaceuticals for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Myanmar (Burma)
Brand Name : MACEF
Dosage Form : Powder for Injection
Dosage Strength : 1G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Myanmar (Burma)
Regulatory Info :
Registration Country : Italy
Brand Name : Maxipime
Dosage Form : Cefepime 2.000Mg 1 Unit Parenteral Use
Dosage Strength : 1 ampoule EV 2 g + 1 ampoule solv 10 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Australia
Brand Name : Cefepime Kabi
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Vial
Dosage Strength : 1000MG; 125MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Powder for Injection
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : INJECTABLE
Dosage Strength : 1000MG
Packaging : Vial
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cefepime OrPha
Dosage Form : Dry Sub
Dosage Strength : 1g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country :
Brand Name :
Dosage Form : Powder for Solution for Injection / Infusion
Dosage Strength : 1G
Packaging : 1 and 10 vials
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 2g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 1g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
